Innovation Leadership OXGENE's reputation for pioneering gene therapy technologies and development platforms positions it as a strategic partner for organizations seeking cutting-edge solutions in cell and gene therapy manufacturing and discovery.

Recent Acquisitions Following its acquisition by Altaris Capital Partners in March 2025, OXGENE may pursue expansion efforts or new project collaborations, offering opportunities for service providers to align with its growth strategy.

Industry Recognition Having received the Queen's Award for Enterprise in 2021, OXGENE demonstrates a track record of excellence and innovation, making it an attractive client for advanced biotech service providers and technology vendors.

Strategic Partnerships OXGENE's collaborations with companies like Wugen highlight its openness to partnerships that enhance the accessibility and manufacturability of life-saving therapies, opening avenues for joint technology and manufacturing solutions.

Growth Focus With a global reputation of developing scalable gene therapy platforms and a focus on expanding capabilities, there are opportunities to offer custom engineering, automation, or manufacturing support to support its innovative projects.